Glaukos Corp (NYSE:GKOS) saw a large increase in short interest during the month of July. As of July 15th, there was short interest totalling 3,239,000 shares, an increase of 6.1% from the June 15th total of 3,054,100 shares. Based on an average daily volume of 361,300 shares, the short-interest ratio is presently 9.0 days. Currently, 9.5% of the company’s stock are short sold.

In other Glaukos news, CFO Joseph E. Gilliam sold 2,500 shares of the stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $73.25, for a total value of $183,125.00. The sale was disclosed in a filing with the SEC, which is available through this link. Over the last three months, insiders sold 27,846 shares of company stock worth $2,032,121. Insiders own 8.70% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Prudential Financial Inc. boosted its holdings in Glaukos by 45.7% in the fourth quarter. Prudential Financial Inc. now owns 4,560 shares of the medical instruments supplier’s stock worth $256,000 after acquiring an additional 1,430 shares in the last quarter. Raymond James & Associates boosted its holdings in Glaukos by 21.2% in the fourth quarter. Raymond James & Associates now owns 18,449 shares of the medical instruments supplier’s stock worth $1,036,000 after acquiring an additional 3,222 shares in the last quarter. Advisor Group Inc. boosted its holdings in Glaukos by 97.6% in the fourth quarter. Advisor Group Inc. now owns 3,439 shares of the medical instruments supplier’s stock worth $192,000 after acquiring an additional 1,699 shares in the last quarter. United Services Automobile Association boosted its holdings in Glaukos by 21.2% in the fourth quarter. United Services Automobile Association now owns 5,940 shares of the medical instruments supplier’s stock worth $334,000 after acquiring an additional 1,040 shares in the last quarter. Finally, California State Teachers Retirement System boosted its holdings in Glaukos by 5.6% in the fourth quarter. California State Teachers Retirement System now owns 53,332 shares of the medical instruments supplier’s stock worth $2,996,000 after acquiring an additional 2,850 shares in the last quarter. 95.73% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NYSE GKOS traded up $0.80 during mid-day trading on Friday, reaching $76.24. The company had a trading volume of 328,620 shares, compared to its average volume of 284,962. The company has a current ratio of 6.72, a quick ratio of 6.23 and a debt-to-equity ratio of 0.07. The stock has a 50 day simple moving average of $75.31. The stock has a market cap of $2.78 billion, a PE ratio of -206.05 and a beta of 1.61. Glaukos has a 52-week low of $36.89 and a 52-week high of $83.14.

Glaukos (NYSE:GKOS) last posted its earnings results on Wednesday, May 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.08. The firm had revenue of $54.03 million for the quarter, compared to the consensus estimate of $50.13 million. Glaukos had a negative net margin of 5.93% and a negative return on equity of 6.90%. Research analysts predict that Glaukos will post -0.3 earnings per share for the current fiscal year.

A number of brokerages have commented on GKOS. BTIG Research reissued a “hold” rating on shares of Glaukos in a research report on Wednesday, May 22nd. Zacks Investment Research downgraded shares of German American Bancorp. from a “buy” rating to a “hold” rating in a research report on Tuesday, April 30th. Finally, BMO Capital Markets increased their target price on shares of goeasy from C$55.00 to C$60.00 in a research report on Thursday, May 9th. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $72.56.

About Glaukos

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery.

Read More: How to trade on quiet period expirations

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.